Axogen Inc (AXGN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 64/100
On August 26, 2026, Axogen Inc (AXGN) shares rose 3.3% to a current price of $51.58, continuing a strong upward trend. Over the past year, the stock has surged
AXGN - AxoGen, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$53.20
DETAILS
HIGH:
$60.00
LOW:
$48.00
MEDIAN:
$53.00
CONSENSUS:
$53.20
UPSIDE:
2.84%
Stock News
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Atlassian, Dick’s Sporting Goods, EPAM Systems, GoDaddy, Intuit, Jersey Mike’s Subs, JFrog, Lattice Semiconductor, and More
Wall Street analysts are reshuffling their bets ahead of a critical inflation report and NVIDIA earnings that could jolt markets in either direction. Find out which names got upgraded, cut, or newly covered before the opening bell Wednesday.
Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel
Axogen is transforming from a niche tissue supplier into a comprehensive nerve care platform, underpinned by FDA approval, stronger reimbursement, and expanding clinical evidence. Q2 2026 revenue grew 23.1% to $69.7M, with raised full-year guidance and strong elective market traction, though gross margin declined due to product mix and biologic costs. Avance's FDA biologic approval grants 12 years of exclusivity, regulatory credibility, and improved payer coverage, positioning AXGN as a category leader with significant market opportunity.
AxoGen (NASDAQ:AXGN) Shares Gap Down Following Weak Earnings
AxoGen, Inc. (NASDAQ: AXGN - Get Free Report)'s stock price gapped down prior to trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $41.15, but opened at $38.31. AxoGen shares last traded at $44.5120, with a volume of 317,776 shares trading hands. The medical equipment provider reported
Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript
Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript
AxoGen Q2 Earnings Call Highlights
AxoGen NASDAQ: AXGN reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target markets. The company raised its full-year revenue outlook to at least $279 million, representing growth of at least 24%, while lowering its gross-margin expectation to at least 73% due to product-mix changes tied to faster-than-expected growth in breast reconstruction.
AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago.
Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology
/PRNewswire/ -- Trace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-targeted imaging agents, today announced it has received a
Axogen, Inc. Reports Second Quarter 2026 Financial Results
ALACHUA, Fla. and TAMPA, Fla.
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
ALACHUA, Fla. and TAMPA, Fla. , July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026.
AxoGen, Stock Of The Day, Offers Entry After Bullish Rebound
AxoGen, Stock Of the Day, is flashing a buy signal. Ten out of 10 analysts are bullish about AxoGen after strong earnings and raised 2026 guidance.
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AxoGen NASDAQ: AXGN President and CEO Michael Dale said the company's growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified.
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla.
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
AxoGen (AXGN) Q1 Earnings Lag Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.02 per share a year ago.
Axogen, Inc. Reports First Quarter 2026 Financial Results
ALACHUA, Fla. and TAMPA, Fla.
Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million
This healthcare firm develops nerve repair solutions for hospitals and specialists in the U.S. and select global markets.
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Price Targets
AxoGen initiated with a Buy at Truist
$60.00
(was $49.93)
Truist Financial
AxoGen, Inc. (AXGN) PT Raised to $53 at H.C. Wainwright
$53.00
(was $41.37)
Yi Chen
·
H.C. Wainwright
AxoGen, Inc. (AXGN) PT Raised to $55 at Citizens on Q2 Performance
$55.00
(was $41.37)
Truist Financial
AxoGen price target raised to $55 from $50 at Jefferies
$55.00
(was $41.37)
Jefferies
AxoGen price target raised to $48 from $41 at Raymond James
$48.00
(was $41.79)
Raymond James
AxoGen price target raised to $50 from $45 at Canaccord
$50.00
(was $41.99)
Caitlin Roberts
·
Canaccord Genuity
AxoGen price target raised to $50 from $39 at H.C. Wainwright
$50.00
(was $41.99)
H.C. Wainwright
AxoGen price target raised to $45 from $40 at Canaccord
$45.00
(was $37.41)
Canaccord Genuity
AxoGen price target raised to $41 from $36 at Raymond James
$41.00
(was $35.00)
Jayson Bedford
·
Raymond James
AxoGen initiated with an Overweight at Wells Fargo
$40.00
(was $35.25)
Wells Fargo
AxoGen price target raised to $39 from $26 at H.C. Wainwright
$39.00
(was $33.70)
H.C. Wainwright
AxoGen price target raised to $37 from $27 at Canaccord
$37.00
(was $32.85)
Canaccord Genuity
AxoGen, Inc. (AXGN) PT Raised to $36 at Raymond James
$36.00
(was $33.19)
Jayson Bedford
·
Raymond James
AxoGen price target raised to $40 from $30 at Lake Street
$40.00
(was $32.10)
Frank Takkinen
·
Lake Street
AxoGen price target raised to $36 from $29 at Jefferies
$36.00
(was $28.33)
Jefferies
AxoGen initiated with an Outperform at Mizuho
$40.00
(was $28.65)
Mizuho Securities
AxoGen price target raised to $26 from $25 at H.C. Wainwright
$26.00
(was $22.86)
H.C. Wainwright
AxoGen price target raised to $27 from $24 at Canaccord
$27.00
(was $22.25)
Canaccord Genuity
AxoGen price target raised to $34 from $26 at Citizens JMP
$34.00
(was $22.25)
JMP Securities
AxoGen initiated with a Buy at H.C. Wainwright
$25.00
(was $17.26)
Yi Chen
·
H.C. Wainwright